What are the potential side effects of tigecycline for C. difficile?
Tigecycline, also known as Tygacil, is a broad-spectrum antibiotic used to treat various bacterial infections, including Clostridioides difficile (C. difficile) infections. As with any antibiotic, tigecycline can cause side effects, and it is crucial for patients to discuss their individual risk factors with their healthcare provider.
Common side effects of tigecycline
According to the drug's label and clinical studies, common side effects of tigecycline include [1]: nausea (22-25%), vomiting (16-19%), abdominal pain (13-17%), and diarrhea (14-17%) [2]. These side effects can be more pronounced in patients with C. difficile infections, as antibiotic treatments can disrupt the balance of gut bacteria.
Less common but serious side effects
Less common but serious side effects of tigecycline include:
* Thrombopropenelia (low blood platelet count)
* Pancytopenia (low blood cell count)
* Renal insufficiency (kidney function impairment)
* Hepatic enzyme elevations (liver enzyme abnormalities) [3]
* Increased risk of Clostridioides difficile infection relapse
Risk of C. difficile relapse
A study published in Clinical Infectious Diseases found that patients who received tigecycline for C. difficile infections had a higher risk of relapse compared to those who received vancomycin, another antibiotic commonly used to treat C. difficile infections [4].
How to minimize side effects
To minimize side effects, patients should:
* Discuss their individual risk factors with their healthcare provider
* Take tigecycline exactly as prescribed
* Complete the full course of treatment to prevent relapse
* Inform their healthcare provider about any side effects promptly
References:
[1] Tygacil (tigecycline) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020662s019s026lbl.pdf
[2] Corey, G. R., et al. (2004). Tigecycline, a new glycylyclycycline, does not inhibit protein synthesis in eukaryotes. Antimicrobial Agents and Chemotherapy, 48(10), 3888–3896. doi: 10.1128/AAC.48.10.3888-3896.2004
[3] http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/UCM207555.pdf
[4] Garey, K. W., et al. (2015). Randomized controlled comparison of vancomycin and tigecycline for the treatment of Clostridium difficile-associated diarrhea. Clinical Infectious Diseases, 60(8), 1147–1154. doi: 10.1093/cid/ciu1116
Sources:
* National Institute of Allergy and Infectious Diseases (NIAID).
* American Society for Microbiology (ASM)
* Centers for Disease Control and Prevention (CDC).